Guidance
Interesting shortcuts
EFFRA Members' Perspectives
News Dashboard
Structured Wiki
Search
FoF and Made in Europe Partnership
Demonstrators, pilots, prototypes
Exploitable result(s)
Significant innovations and lessons learned, training aspects
Report - Video - Presentation - Publication....?
Project clusters
Company perspectives
Manufacturing future products
Manufacturing performance characteristics
Technologies and enablers
ICT performance characteristics
Standards, technical committees and working groups
Contribution of R&I projects to standardisation
Regulatory and policy aspects
Standards - other classifications
Business model aspects
Pathways
MiE SRIA R&I Priorities
MiE WP26-27 Consultation - Potential Research Topics only
MiE WP26-27 Consultation and context pointers
MiE WP26-27 Consultation with pointers to WP25-27 consultation
MiE KPIs
Relevant (future) calls
EU-Programme-Call
NACE code
EFFRA Organisations - members
EFFRA WG pointers
Pathways
Pathways
Projects
Projects
Resources
Resources
Project ideas
Project ideas
People & organisations
People
Organisations
portal@effra.eu
Visit the EFFRA website
Login
Structured Wiki
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.7. Innovative Medicines Initiative 2 (IMI2)
H2020-EU.3.1.7. Innovative Medicines Initiative 2 (IMI2)
H2020-EU.3.1.7.0. Cross-cutting call topics
H2020-JTI-IMI2-2014-01-two-stage
H2020-JTI-IMI2-2014-02-single-stage
H2020-JTI-IMI2-2015-03-two-stage
H2020-JTI-IMI2-2015-05-two-stage
H2020-JTI-IMI2-2015-06-two-stage
H2020-JTI-IMI2-2015-07-two-stage
H2020-JTI-IMI2-2015-08-single-stage
H2020-JTI-IMI2-2016-09-two-stage
H2020-JTI-IMI2-2016-10-two-stage
H2020-JTI-IMI2-2017-11-single-stage
H2020-JTI-IMI2-2017-12-two-stage
H2020-JTI-IMI2-2017-13-two-stage
H2020-JTI-IMI2-2018-14-two-stage
H2020-JTI-IMI2-2018-15-two-stage
H2020-JTI-IMI2-2018-16-single-stage
H2020-JTI-IMI2-2019-17-two-stage
H2020-JTI-IMI2-2019-18-two-stage
H2020-JTI-IMI2-2019-19-single-stage
H2020-JTI-IMI2-2020-21-single-stage
H2020-EU.3.1.7.1. Antimicrobial resistance
H2020-EU.3.1.7.12. Vaccine
H2020-JTI-IMI2-2015-03-two-stage
H2020-EU.3.1.7.13. Other
H2020-JTI-IMI2-2014-02-single-stage
H2020-JTI-IMI2-2015-04-two-stage
H2020-EU.3.1.7.4. Diabetes
H2020-EU.3.1.7.5. Neurodegenerative diseases
H2020-EU.3.1.7.6. Psychiatric diseases
H2020-EU.3.1.7.8. Immune-mediated diseases